Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review

Jessica D. Rich; Stephen M. Clark; Yuri Fedoriw; Valerie Jewells; William Wood; Christopher Dittus

doi:10.1002/ccr3.2257

Clinical Case Reports (Oct 2019)

Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review

Jessica D. Rich,
Stephen M. Clark,
Yuri Fedoriw,
Valerie Jewells,
William Wood,
Christopher Dittus

Affiliations

Jessica D. Rich: University of Tennessee Health and Science Center Memphis Tennessee
Stephen M. Clark: Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina
Yuri Fedoriw: Department of Pathology and Laboratory Medicine University of North Carolina at Chapel Hill Chapel Hill North Carolina
Valerie Jewells: Division of Neuroradiology University of North Carolina at Chapel Hill Chapel Hill North Carolina
William Wood: Division of Hematology and Oncology University of North Carolina at Chapel Hill Chapel Hill North Carolina
Christopher Dittus: Division of Hematology and Oncology University of North Carolina at Chapel Hill Chapel Hill North Carolina

DOI: https://doi.org/10.1002/ccr3.2257
Journal volume & issue: Vol. 7, no. 10
pp. 1957 – 1961

Abstract

Read online

Abstract Central nervous system (CNS)‐relapsed mantle cell lymphoma (MCL) is a rare, aggressive non‐Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non‐Hodgkin lymphomas and may be considered as successful treatment for CNS‐relapsed MCL in the future as well.

Published in Clinical Case Reports

ISSN: 2050-0904 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: https://onlinelibrary.wiley.com/journal/20500904

About the journal

Abstract

Keywords